The company’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 39.6% from the same quarter last year to ₹352 crore from ₹252 crore earlier.
EBITDA margin expanded by nearly 300 basis points to 23.9% from 21% from the year-ago period.
Net profit for the period increased by 32.6% year-on-year to ₹201.5 crore from ₹152 crore. Revenue grew 22.8% to ₹1,470.6 crore from ₹1,197.4 crore during the same quarter last year.
The board of Granules has also recommended a final dividend of ₹1.75 per share.
In its post earnings statement, Granules India stated that the revenue share from North America stood at 72%, compared to 79% during the same quarter last year, while the share from Europe rose to 17% from 8% in the year-ago period.
Net debt for the company saw a reduction of ₹304 crore during the same quarter last year to ₹402.1 crore.
The management attributed the earnings performance to continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. CMD Krishna Prasad Chigurupati also said that the quarter reflected improving earnings quality and a sustained advancement in complex generics and the peptides CDMO platform.
Back in December 2025, the company’s board had approved the issuance of 2.5 crore warrants, each of which will be convertible to fully paid up equity shares of the company for a total consideration of ₹1,462.5 crore. The warrant issue was approved at a price of ₹585 apiece.
During the quarter, the company received an aggregate of ₹365.6 crore on February 23, which is 25% of the total consideration of the warrants.
Shares of Granules India have surged to the highs of the day, currently trading 2.2% higher at a record high of ₹721. Shares have risen 13% so far in April, which makes it the best month that the stock has had since May last year, during which the stock has risen 16%.
